CBPO [China Biologic Products] 8-K: (Original Filing)
[FOR RELEASE October 11, 2016 China Biologic Receives CFDA Clinical Trial Approval for Human Antithrombin III BEIJING, China – October 11, 2016 – ATIII is intended to treat hereditary and acquired ATIII deficiency in connection with surgical or obstetrical procedures, and to treat thromboembolism. No]
